MA38656A1 - Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose - Google Patents

Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose

Info

Publication number
MA38656A1
MA38656A1 MA38656A MA38656A MA38656A1 MA 38656 A1 MA38656 A1 MA 38656A1 MA 38656 A MA38656 A MA 38656A MA 38656 A MA38656 A MA 38656A MA 38656 A1 MA38656 A1 MA 38656A1
Authority
MA
Morocco
Prior art keywords
inhibitor
cancer
mps
kinase
treatment
Prior art date
Application number
MA38656A
Other languages
English (en)
Inventor
Gerhard Siemeister
Antje Wengner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48576906&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38656(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38656A1 publication Critical patent/MA38656A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une combinaison comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose. La présente invention concerne en outre l'utilisation de ladite combinaison pour le traitement d'un cancer, en particulier du cancer du pancréas, d'un glioblastome, du cancer de l'ovaire, d'un carcinome pulmonaire non à petites cellules, du cancer du sein et/ou du cancer gastrique.
MA38656A 2013-06-11 2014-06-06 Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose MA38656A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13171517 2013-06-11
PCT/EP2014/061772 WO2014198645A1 (fr) 2013-06-11 2014-06-06 Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose

Publications (1)

Publication Number Publication Date
MA38656A1 true MA38656A1 (fr) 2018-05-31

Family

ID=48576906

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38656A MA38656A1 (fr) 2013-06-11 2014-06-06 Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose

Country Status (16)

Country Link
US (1) US20160128988A1 (fr)
EP (1) EP3007692A1 (fr)
JP (1) JP2016520665A (fr)
KR (1) KR20160018534A (fr)
CN (1) CN105283178A (fr)
AU (1) AU2014280354A1 (fr)
CA (1) CA2914742A1 (fr)
CL (1) CL2015003585A1 (fr)
EA (1) EA201600003A1 (fr)
HK (1) HK1219879A1 (fr)
MA (1) MA38656A1 (fr)
MX (1) MX2015017120A (fr)
PH (1) PH12015502757A1 (fr)
SG (1) SG11201509350RA (fr)
TN (1) TN2015000543A1 (fr)
WO (1) WO2014198645A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105377848A (zh) * 2013-06-11 2016-03-02 拜耳制药股份公司 取代的***并吡啶的前体药物衍生物
AU2017248807A1 (en) * 2016-04-15 2018-10-25 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
PT3474841T (pt) 2016-06-22 2022-06-20 Radius Health Inc Métodos de tratamento do cancro de mama ar+
CN106117202B (zh) * 2016-06-29 2018-06-26 四川大学华西医院 具有抗肿瘤活性的[1,2,4]***并[1,5-a]吡啶衍生物晶型
WO2023165603A1 (fr) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Inhibiteur d'adn-pk et son utilisation en combinaison

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5721268A (en) 1991-09-23 1998-02-24 Florida State University C7 taxane derivatives and pharmaceutical compositions containing them
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
ES2218328T5 (es) 1995-11-17 2011-11-11 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Derivados de epotilón, su preparación y utilización.
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
JP2001500851A (ja) 1996-08-30 2001-01-23 ノバルティス アクチエンゲゼルシャフト エポシロンの製造法および製造過程中に得られる中間生産物
CN100344627C (zh) 1996-11-18 2007-10-24 生物技术研究有限公司(Gbf) 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CA2281105A1 (fr) 1997-02-25 1998-09-03 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilones a chaine laterale modifiee
US5902822A (en) 1997-02-28 1999-05-11 Bristol-Myers Squibb Company 7-methylthiooxomethyl and 7-methylthiodioxomethyl paclitaxels
US6117659A (en) 1997-04-30 2000-09-12 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
EP1001951B1 (fr) 1997-07-16 2002-09-25 Schering Aktiengesellschaft Derives de thiazole, leur procede de production et leur utilisation
DE59814067D1 (de) 1997-08-09 2007-09-06 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
EP1042327B1 (fr) 1997-12-04 2003-09-17 Bristol-Myers Squibb Company Procede de reduction d'epothilones d'oxiranyle en epothilones olefiniques
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
EP2343294A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines substituées
EP2343297A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Dérivés de triazolopyridine
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
DK2699575T3 (da) * 2011-04-21 2015-06-22 Bayer Ip Gmbh Triazolopyridiner
WO2012160029A1 (fr) * 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Triazolopyridines substituées
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
WO2014009219A1 (fr) 2012-07-10 2014-01-16 Bayer Pharma Aktiengesellschaft Procédé de préparation de triazolopyridines substituées
WO2014020043A1 (fr) * 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer

Also Published As

Publication number Publication date
KR20160018534A (ko) 2016-02-17
CA2914742A1 (fr) 2014-12-18
CN105283178A (zh) 2016-01-27
CL2015003585A1 (es) 2016-07-08
EA201600003A1 (ru) 2016-06-30
MX2015017120A (es) 2016-10-05
PH12015502757A1 (en) 2016-03-21
EP3007692A1 (fr) 2016-04-20
US20160128988A1 (en) 2016-05-12
JP2016520665A (ja) 2016-07-14
AU2014280354A1 (en) 2015-12-03
SG11201509350RA (en) 2015-12-30
WO2014198645A1 (fr) 2014-12-18
HK1219879A1 (zh) 2017-04-21
TN2015000543A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
CY1122247T1 (el) Αγωγη καρκινων με τη χρηση τροποποιητων ισομορφης κινασης ρι3
MA41013B1 (fr) Compositions comprenant des souches bactériennes
EA202091540A1 (ru) Антитела к lilrb2
MA39034B1 (fr) Composés de quinoline sélectivement substitués
EA201691916A1 (ru) Биарильные ингибиторы киназы
MA38656A1 (fr) Combinaisons pour le traitement du cancer comprenant un inhibiteur de la kinase mps-1 et un inhibiteur de la mitose
EP3575795A3 (fr) Biomarqueurs salivaires pour cancer du sein
WO2014160499A3 (fr) Procédés et compositions pour détecter un cancer du pancréas
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
MY173126A (en) Arylquinazolines
TR201907981T4 (tr) Heteroaromatik bileşikler ve bunların dopamin d1 ligandları olarak kullanımı.
IN2014DN05885A (fr)
EA201491647A1 (ru) Основанные на арилэфирах ингибиторы киназ
MA38495A1 (fr) Compositions et méthodes pour le diagnostic et le traitement de cancers hépatiques
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
MA34598B1 (fr) Procédés et compositions pour traiter le cancer du poumon
MX2023012628A (es) Metodos y composiciones para deteccion y diagnostico de enfermedades renales y enfermedades periodontales.
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
BR112015018433A2 (pt) indicador de desgaste em um sistema composto feito de tijolos de cerâmica à prova de fogo
EP4286853A3 (fr) Compositions présentant une grande spécificité pour l'évaluation du cancer de l'ovaire
MX369175B (es) Métodos para detectar mutantes de akt resistentes a fármacos.
MA38654B1 (fr) Dérivés de type promédicament de triazolopyridines substituées
BR112015016992A8 (pt) uso de agonistas do receptor alfa 7 nicotínico de acetilcolina